Current Funding Opportunities
Click here to visit the NCI grant site.
Use your device's search function to find a specific disease or funding source.
- External Funding
- Internal Grant Opportunities
Funding
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).
The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards
Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Learn More>>
National Cancer Institute Youth Enjoy Science Research Education Program (R25)
The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.
Application Deadline: September 25, 2019
Learn more about this NCI R25 Program>>
Susan G. Komen Career Catalyst Research Grant
- Refining treatment of metastatic breast cancer
- Early detection of metastatic breast cancer
Alex’s Lemonade Stand Foundation (ALSF) is now accepting applications for the ALSF Single-cell Pediatric Cancer Atlas. ALSF seeks to build a Pediatric Cancer Atlas as an open resource for discovery with an initial goal of producing data that can be harmonized. ALSF seeks researchers to create datasets that profile pediatric cancers at a single-cell resolution level. Single-cell profiling can provide insights into the heterogeneity of cells in a tumor and the surrounding tumor microenvironment, as well as variability in the states of cancer cells, all of which can influence the cancer’s response to treatments.
Application Deadline: September 30, 2019
Learn More>>
Burroughs Wellcome Fund - Career Awards for Medical Scientists
The Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides $700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Proposals must be in the area of basic biomedical, disease-oriented, or translational research. Proposals in health services research or involving large-scale clinical trials are not eligible.
Application Deadline: October 1, 2019
Learn More>>
Since 1983, the Life Sciences Research Foundation (LSRF) has funded nearly 550 outstanding postdoctoral fellows in all areas of the life sciences, and raised more than $50 million from generous industries, foundations, and individuals to support this effort.
Application Deadline: 8:00 PM EST on October 1, 2019
Learn More>>
Cancer Research Institute - CRI Irvington Postdoctoral Fellowship Program Applications
The Cancer Research Institute is currently accepting applications for its CRI Irvington Postdoctoral Fellowship Program. The CRI Irvington Fellowship furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists.
Program Note: In recent years, significant advances in immunotherapy have yielded major breakthroughs in cancer treatment. CRI recognizes, however, that getting to the next great breakthrough will require continued investment in fundamental research and training. With this in mind, CRI accepts applications from qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or tumor immunology.
CRI is seeking hypothesis-driven, mechanistic studies in both immunology and tumor immunology that aim to directly impact our understanding of the immune system’s role in cancer.
Application Deadline: October 1, 2019
Learn More>>
Defense Health Program - Department of Defense Melanoma Research Program Funding Opportunities for Fiscal Year 2019 (FY19)
The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP) to support innovative, high-impact melanoma research.
FY19 MRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website.
The FY19 MRP Focus Areas are listed below:
• Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
• Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
• Therapeutic Prevention
• Minimal Residual Disease
• Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)
The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.
https://cdmrp.army.mil/funding/mrp
Concept Award
Investigators at or above postdoctoral fellow (or equivalent)
• Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.
• Emphasis is on Innovation.
• Preliminary data is strongly discouraged.
• Clinical trials are not allowed.
• Blinded review.
• The maximum allowable funding for the entire period of performance is $75,000 in direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• The maximum period of performance is 1 year.
LOI Deadline: October 2, 2019; Application Deadline: October 23, 2019
Learn More>>
American Lung Association Lung Cancer Discovery Award
Intended to support independent investigators conducting clinical, laboratory, epidemiological or any groundbreaking project aimed at revolutionizing our current understanding of lung cancer and improving diagnostic, clinical and treatment methods. A Letter of Intent (LOI) is required for this award.
Letter of Intent (LOI) Deadline: October 3, 2019
Learn More>>
Maximizing the Scientific Value of Existing Biospecimen Collections (R21)
The purpose of this FOA is to invite R21 applications to stimulate exploratory research relevant to the mission of the FDA - Center for Tobacco Products using existing (publicly available) biospecimens currently stored in repositories in the United States.
Application Deadline: October 8, 2019
Learn more about this R21 FDA Award>>
Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21)
The purpose of this FOA is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the FDA- Center for Tobacco Products.
Application Deadline: October 8, 2019
Learn more about this R21 FDA Tobacco Award>
Pfizer Global Medical Grants (GMG) - 2019 Global Breast Cancer Competitive Research Grant Program
The intent of this request for proposal (RFP) is to invite investigators from across the global to submit innovative proposals focusing in the following areas:
In hormone receptor positive metastatic breast cancer:
- Treatment strategies to overcome palbociclib + endocrine treatment resistance
- Novel treatment concepts of adding immuno-oncology (IO) agents to palbociclib + endocrine therapy
In metastatic breast cancer:
- Novel treatment strategies utilizing talazoparib beyond gBRCA mutation
- Novel treatment strategies to overcome talazoparib resistance or improve tumor sensitization to talazoparib
Letter of Intent Deadline: October 15, 2019
Learn More>>
NIBIB Trailblazer Award for New and Early Stage Investigators (R21)
This Trailblazer Award is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and behavioral sciences.
Application Deadline: October 16, 2019
Learn more about this NIBIB Award>>
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)
The purpose of this FOA is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations.
Application Deadline: October 16, 2019
Learn more about this NCI R21 Award>>
NCI Clinical and Translational Exploratory/Developmental Studies (R21)
This FOA supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials.
Application Deadline: October 18, 2019
Learn more about the NCI Clinical and Translational Study>>
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21/R03)
This FOA encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine.
Application Deadline: October 16, 2019
Learn more about the HPV Uptake R21>>
Learn more about the HPV Uptake R03>>
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)
This FOA encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent HPV vaccine.
Application Deadline: October 17, 2019
Learn more about the HPV Uptake R01>>
Neural Regulation of Cancer (R01) (R21)
This FOA encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.
Application Deadline: October 21, 2019
Learn more about the neural regulation R01>>
Learn more about the neural regulation R21>>
Revision Applications for Mechanisms of Cancer Drug Resistance (R01), (U01), (U54), (P01), (P50)
This FOA is associated with the Beau Biden Cancer MoonshotSM Initiative. The purpose is to support the addition of new aims and directions to ongoing NCI-funded Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.
Application Deadline: October 24, 2019
Learn more about the Drug Resistance Moonshot Initiative>>
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01) (R21)
This FOA invites applications for intervention research designed to support caregivers of adult cancer patients.
Application Deadline (R01): October 17, 2019 Application Deadline (R21): November 16, 2019
Learn more about the Healthcare Utilization R01 and R21>>
2020 Pershing Square Sohn Prize for Young Investigators in Cancer Research
This award provides greater New York City area-based early career scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking.
LOI's Due: November 4, 2019
Learn More about the Pershing Award>>
Terri Brodeur Breast Cancer Foundation Grant Program
This award is intended to support scientists at earlier stages of their careers to enable the development of independent programs and compelling careers in breast cancer research.
Application Deadline: November 16, 2019
Learn More about the Terri Brodeur Grant>>